These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25404582)

  • 1. Cochrane in context: Rifamycins compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):295-7. PubMed ID: 25404582
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
    Hamada Y; Ford N; Schenkel K; Getahun H
    Int J Tuberc Lung Dis; 2018 Dec; 22(12):1422-1428. PubMed ID: 30606313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
    Hickey MD; Quan DJ; Chin-Hong PV; Roberts JP
    Liver Transpl; 2013 Apr; 19(4):457-61. PubMed ID: 23526600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of rifabutin in the treatment of pulmonary tuberculosis.
    Grassi C; Peona V
    Clin Infect Dis; 1996 Apr; 22 Suppl 1():S50-4. PubMed ID: 8785257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An update on the antibiotic therapy of tuberculosis].
    Rossi G
    Recenti Prog Med; 1999 May; 90(5):241-3. PubMed ID: 10380549
    [No Abstract]   [Full Text] [Related]  

  • 7. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Mar; 49(9):185-9. PubMed ID: 11795500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
    Goldberg SV; Hanson D; Peloquin CA
    Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
    [No Abstract]   [Full Text] [Related]  

  • 10. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Radtke KK; Hibma JE; Hesseling AC; Savic RM
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703775
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rifabutin--a new antituberculous antibiotic].
    Antibiot Khimioter; 1997; 42(5):47-8. PubMed ID: 9254590
    [No Abstract]   [Full Text] [Related]  

  • 13. New guidelines for latent tuberculosis.
    Mushtaq A
    Lancet Infect Dis; 2020 Apr; 20(4):414. PubMed ID: 32222207
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifamycins, Alone and in Combination.
    Rothstein DM
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27270559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
    Klemens SP; Grossi MA; Cynamon MH
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2245-8. PubMed ID: 7840552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Another step on the path to better TB therapies.
    Vernon A; Burman W; Horsburgh CR
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):1-2. PubMed ID: 11931394
    [No Abstract]   [Full Text] [Related]  

  • 19. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Non-Replicating
    Egorova A; Salina EG; Makarov V
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.